Connect Biopharma Announces Two Presentations at the European Respiratory Society (ERS) Congress 2025

Rhea-AI Summary

Connect Biopharma (Nasdaq: CNTB) announced two poster presentations at the upcoming European Respiratory Society (ERS) Congress 2025, scheduled for September 27 - October 1, 2025, in Amsterdam and virtually. Both presentations focus on Rademikibart, the company's treatment for asthma.

Dr. Raúl Collazo will present research on Rademikibart's effectiveness in moderate-to-severe asthma and its impact on FEV1 improvements in Type 2 Asthma. The presentations will take place on September 29th at 8:00 a.m. CET during Session #218 on Biologics for Asthma and Allergic Rhinitis. The presentations will later be available on Connect's website.

SAN DIEGO, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced two poster presentations at the European Respiratory Society (ERS) Congress 2025, taking place September 27 – October 1, 2025, in Amsterdam, Netherlands and virtually.

The presentation details are as follows:

Abstract Title: Rademikibart in Moderate-to-Severe Asthma: Impact of Eosinophils and Regional Differences on Response
Poster Number: PA2480
Presenter: Raúl Collazo, Ph.D.
Session#218: Biologics for Asthma and Allergic Rhinitis: Novel Trial Data
Date and Time: Monday, September 29^th from 8:00 a.m. – 9:30 a.m. CET

Abstract Title: Rapid and Sustained FEV₁ Improvements with Rademikibart in Type 2 Asthma: Impact of Eosinophils and F_ENO
Poster Number: PA2481
Presenter: Raúl Collazo, Ph.D.
Session#218: Biologics for Asthma and Allergic Rhinitis: Novel Trial Data
Date and Time: Monday, September 29^th from 8:00 a.m. – 9:30 a.m. CET

Following the presentations, each presentation will be available on Connect’s website under the presentations and publications section.

About Rademikibart
Rademikibart is a fully human monoclonal antibody targeting interleukin-4 receptor alpha (IL-4Rα), a common subunit of interleukin-4 receptor (IL-4) and interleukin-13 receptor (IL-13). We believe that by binding with IL-4Rα, rademikibart can block the functions of IL-4 and IL-13 effectively, thereby blocking the T helper 2 (Th2) inflammatory pathway to achieving the goal of treating Th2 related inflammatory diseases such as atopic dermatitis and asthma.

About Connect Biopharma
Connect Biopharma is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and COPD. Headquartered in San Diego, California, the Company is advancing rademikibart, a next-generation, potentially best-in-class antibody designed to target IL-4Rα. The Company is currently conducting global clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD, areas with significant unmet need. Connect also has an exclusive license and collaboration agreement for rademikibart with Simcere in China.

For more information visit www.connectbiopharma.com.

Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended (the Act). Forward-looking statements are statements that are not of historical fact and include, without limitation, statements regarding future events, our cash balance, financial guidance, future financial and operating results and related expectations, business strategy and plans, prospective products (as well as their potential to achieve a differentiated, competitive, or favorable benefit or profile or trend, including on safety, tolerability, improvement, maintenance, clinical response, dosing, efficacy and/or convenience), planned or expected product approval applications or approvals, anticipated milestones, expected data readouts and enrollments, research and development plans and costs, potential future partnerships, expectations about existing partnerships, timing and likelihood of success, objectives of management for future operations, future results of anticipated product development efforts, adequacy of existing cash and potential partnership funding to fund operations and capital expenditure requirements, anticipated patient populations or market opportunities for our prospective products, if approved, as well as statements regarding industry trends. These statements are based on management’s current expectations of future events only as of the date of this press release and are inherently subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control, including, among other things: the ability of our clinical trials to demonstrate safety and efficacy of our product candidates and other positive results; whether we will need expanded or additional trials in order to obtain regulatory approval for our product candidates; our ability to obtain and maintain regulatory approval of our product candidates; existing regulations and regulatory developments in the U.S., the People’s Republic of China, Europe and other jurisdictions; the ability of our current cash and investments position to support planned operations; our plans and ability to obtain, maintain, protect and enforce our intellectual property rights and our proprietary technologies, including extensions of existing patent terms where available; our continued reliance on third parties to conduct additional clinical trials of our product candidates, and for the manufacture of our product candidates for preclinical studies and clinical trials; and the degree of market acceptance of our product candidates, if approved, by physicians, patients, healthcare payors and others in the medical community.

Words such as “aim,” “anticipate,” “believe,” “could,” “expect,” “feel,” “goal,” “intend,” “may,” “optimistic,” “plan,” “potential,” “promising,” “will,” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. The inclusion of forward-looking statements should not be regarded as a representation by Connect Biopharma that any of its expectations, projections or plans will be achieved. Actual results may differ materially due to the risks and uncertainties inherent in our business and other risks described in our filings with the SEC. Further information regarding these and other risks is included under the heading “Risk Factors” in our annual and periodic reports filed with the SEC. These forward-looking statements should not be taken as forecasts or promises nor should they be taken as implying any indication, assurance or guarantee that the assumptions on which such forward-looking statements have been made are correct or exhaustive or, in the case of the assumptions, fully stated in this presentation. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You are cautioned not to place undue reliance on the scientific data presented or these forward-looking statements, which speak only as of the date of this presentation. Except as required by law, Connect Biopharma undertakes no obligation to publicly update any forward-looking statements, whether because of new information, future events or otherwise. Connect Biopharma claims the protection of the safe harbor for forward-looking statements contained in the Act for all forward-looking statements.

This press release discusses our product candidate, rademikibart, which is under clinical investigation and has not yet been approved for marketing by the U.S. Food and Drug Administration, the National Medical Products Administration, or by any other regulatory agency. No representation is made as to the safety or effectiveness of rademikibart for the uses for which it is being studied. The trademarks included herein are the property of the owners thereof and are used for reference purposes only.

Investor Relations Contact:
Alex Lobo 
Precision AQ 
Alex.lobo@precisionaq.com 
(212) 698-8802

Media Contact:
Ignacio Guerrero-Ros, Ph.D., or David Schull
Russo Partners, LLC
Ignacio.guerrero-ros@russopartnersllc.com 
David.schull@russopartnersllc.com 
(858) 717-2310 or (646) 942-5604

FAQ

When is Connect Biopharma (CNTB) presenting at the ERS Congress 2025?

Connect Biopharma will present two posters on Monday, September 29th, 2025, from 8:00 a.m. to 9:30 a.m. CET during Session #218.

What will Connect Biopharma present about Rademikibart at ERS Congress 2025?

Connect Biopharma will present two posters about Rademikibart's impact on moderate-to-severe asthma and its effects on FEV1 improvements in Type 2 Asthma, including the influence of eosinophils.

Where can investors find Connect Biopharma's ERS Congress 2025 presentations?

The presentations will be available on Connect Biopharma's website under the presentations and publications section after the conference.

Who is presenting Connect Biopharma's research at ERS Congress 2025?

Dr. Raúl Collazo, Ph.D. will present both posters at the conference.